Alambic Investment Management L.P. increased its position in STAAR Surgical (NASDAQ:STAA) by 41.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,750 shares of the medical instruments supplier’s stock after purchasing an additional 2,850 shares during the period. Alambic Investment Management L.P.’s holdings in STAAR Surgical were worth $468,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of the stock. Winslow Evans & Crocker Inc. purchased a new stake in shares of STAAR Surgical in the third quarter worth $142,000. Engineers Gate Manager LP purchased a new stake in shares of STAAR Surgical in the second quarter worth $208,000. Tower Research Capital LLC TRC grew its stake in shares of STAAR Surgical by 367.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,877 shares of the medical instruments supplier’s stock worth $213,000 after acquiring an additional 5,405 shares during the last quarter. Harvest Fund Management Co. Ltd purchased a new stake in shares of STAAR Surgical in the third quarter worth $222,000. Finally, Xact Kapitalforvaltning AB purchased a new stake in shares of STAAR Surgical in the third quarter worth $278,000. 84.11% of the stock is currently owned by institutional investors.
STAAR Surgical stock opened at $36.43 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.76 and a current ratio of 5.35. STAAR Surgical has a one year low of $13.60 and a one year high of $54.00. The firm has a market cap of $1.61 billion, a P/E ratio of 3,643.00 and a beta of 2.05.
A number of equities research analysts have recently commented on the company. BidaskClub cut STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Monday. Benchmark reissued a “buy” rating and issued a $54.00 target price (up from $45.00) on shares of STAAR Surgical in a research note on Monday, September 24th. Zacks Investment Research raised STAAR Surgical from a “hold” rating to a “strong-buy” rating and set a $51.00 target price on the stock in a research note on Thursday, November 8th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $43.00 target price (up from $32.00) on shares of STAAR Surgical in a research note on Thursday, August 2nd. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $45.25.
STAAR Surgical Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
Featured Article: Consumer behavior in bull markets
Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical (NASDAQ:STAA).
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.